Skyrizi is the first treatment for Crohn’s that works differently by specifically targeting the interleukin-23 (IL-23) protein, which is one of the key proteins responsible for inflammation. Skyrizi also treats moderately to severely active rheumatoid arthritis (RA) and active psoriatic arthritis.
By targeting IL-23, SKYRIZI can help reduce the excess inflammation that may contribute to Crohn’s symptoms. It is used in adult patients to lessen the symptoms of moderately to severely active Crohn’s disease (CD) in patients who have tried and failed the usual treatments.
Adults with Crohn’s disease will receive their starter doses with SKYRIZI through a vein in the arm (intravenous infusion) in a healthcare facility by a healthcare provider. After completing the starter doses, patients will receive SKYRIZI as an injection under the skin (subcutaneous injection) using the prefilled cartridge with the On-Body Injector (OBI).
Most common (>3%) adverse reactions with SKYRIZI in Crohn’s Disease are upper respiratory infections, headache and arthralgia in induction and arthralgia, injection site reactions, abdominal pain, anemia, pyrexia, back pain arthropathy, and urinary tract infections in maintenance.
We offer expert infusion therapy without the hassle or cost of the hospital. We employ highly trained medical staff that work with health insurance companies & physicians to provide our patients with convenient care.
At Omega Health Clinics, we’re committed to offering affordable treatment, with upfront pricing and no hidden costs. Here’s how we make it happen.
